SOLIRIS (Eculizumab)

Soliris® is a first-in-class terminal complement inhibitor discovered, developed, and commercialized by Alexion. Soliris®  works by inhibiting terminal complement, a part of the immune system that, when activated in an uncontrolled manner, plays a role in serious diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG).1

Soliris®  has earned some of the pharmaceutical industry’s highest honors for innovation, including the 2008 Prix Galien USA Award for Best Biotechnology Product and the 2009 Prix Galien France Award in the category of Drugs for Rare Diseases.

INDICATIONS & IMPORTANT SAFETY INFORMATION FOR SOLIRIS® (ECULIZUMAB)

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Soliris is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.

 

  • Atypical Hemolytic Uremic Syndrome (aHUS)

Soliris is indicated for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

  • Generalized Myasthenia Gravis (gMG)

Soliris is indicated for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive.

Limitation of Use

  • Soliris is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

sol.png

8080 Ravines Edge Court Columbus, Ohio 43235